$SPRO
Spero Therapeutics Inc

2019 Q4 Form 10-K Financial Statement

#000156459020010998 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $696.0K $4.643M $2.156M
YoY Change -58.87% 605.62% 365.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.790M $4.130M $3.780M
YoY Change 3.84% 31.95% 23.53%
% of Gross Profit
Research & Development $25.73M $18.50M $12.03M
YoY Change 181.82% 118.64% 63.14%
% of Gross Profit
Depreciation & Amortization -$110.0K $490.0K $190.0K
YoY Change -178.57% 512.5% 111.11%
% of Gross Profit
Operating Expenses $29.51M $22.63M $15.81M
YoY Change 131.0% 95.19% 51.5%
Operating Profit -$17.99M -$13.65M
YoY Change 64.47% 36.92%
Interest Expense $1.550M $268.0K $502.0K
YoY Change -43.22% 3246.67%
% of Operating Profit
Other Income/Expense, Net -$650.0K $268.0K $502.0K
YoY Change -232.65% -43.22% 3246.67%
Pretax Income -$24.99M -$17.72M -$13.15M
YoY Change 135.75% 69.41% 32.03%
Income Tax
% Of Pretax Income
Net Earnings -$24.99M -$17.70M -$13.20M
YoY Change 135.74% 69.17% 32.58%
Net Earnings / Revenue -3589.94% -381.22% -612.24%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.311M -$949.6K -$744.2K
COMMON SHARES
Basic Shares Outstanding 19.13M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.00M $93.90M $103.4M
YoY Change -28.94% -28.43% 55.26%
Cash & Equivalents $29.73M $45.60M $71.13M
Short-Term Investments $52.30M $48.30M $32.30M
Other Short-Term Assets $4.800M $2.700M $5.400M
YoY Change -36.0% 125.0% 350.0%
Inventory
Prepaid Expenses
Receivables $1.000M $900.0K
Other Receivables $6.400M $3.000M
Total Short-Term Assets $95.41M $104.0M $112.7M
YoY Change -23.19% -22.24% 59.84%
LONG-TERM ASSETS
Property, Plant & Equipment $2.273M $2.519M $2.689M
YoY Change -21.43% 14.5% 168.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.520M $2.077M $2.449M
YoY Change 111.92% 938.5% 249.86%
Total Long-Term Assets $10.69M $8.540M $9.799M
YoY Change 123.29% 252.89% 366.62%
TOTAL ASSETS
Total Short-Term Assets $95.41M $104.0M $112.7M
Total Long-Term Assets $10.69M $8.540M $9.799M
Total Assets $106.1M $112.5M $122.5M
YoY Change -17.75% -17.34% 68.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.147M $2.524M $1.039M
YoY Change 15.1% 85.04% 48.43%
Accrued Expenses $22.50M $12.30M $7.000M
YoY Change 171.08% 43.02% 27.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.66M $15.06M $8.249M
YoY Change 116.46% 46.51% 24.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.900M $4.400M $4.600M
YoY Change 512.5% 1366.67% 1433.33%
Total Long-Term Liabilities $4.900M $4.400M $4.600M
YoY Change 512.5% 1366.67% 1433.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.66M $15.06M $8.249M
Total Long-Term Liabilities $4.900M $4.400M $4.600M
Total Liabilities $31.53M $19.48M $12.82M
YoY Change 139.75% 84.29% 75.62%
SHAREHOLDERS EQUITY
Retained Earnings -$199.4M -$174.4M -$156.7M
YoY Change 43.99% 36.39%
Common Stock $274.0M $19.00K $19.00K
YoY Change 7.86% 5.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.57M $92.68M $109.3M
YoY Change
Total Liabilities & Shareholders Equity $106.1M $112.5M $122.5M
YoY Change -17.75% -17.34% 68.73%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$24.99M -$17.70M -$13.20M
YoY Change 135.74% 69.17% 32.58%
Depreciation, Depletion And Amortization -$110.0K $490.0K $190.0K
YoY Change -178.57% 512.5% 111.11%
Cash From Operating Activities -$17.37M -$9.660M -$12.07M
YoY Change 28.57% 75.0% 39.7%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$20.00K -$90.00K
YoY Change -95.04% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$3.970M -$15.87M $24.93M
YoY Change -140.93% -78.14% 398.6%
Cash From Investing Activities -$4.100M -$15.89M $24.85M
YoY Change -156.32% -78.12% 397.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.600M 10.00K 8.960M
YoY Change -3211.11% -99.99% -4580.0%
NET CHANGE
Cash From Operating Activities -17.37M -9.660M -12.07M
Cash From Investing Activities -4.100M -15.89M 24.85M
Cash From Financing Activities 5.600M 10.00K 8.960M
Net Change In Cash -15.87M -25.54M 21.74M
YoY Change 147.58% 210.33% -666.15%
FREE CASH FLOW
Cash From Operating Activities -$17.37M -$9.660M -$12.07M
Capital Expenditures -$120.0K -$20.00K -$90.00K
Free Cash Flow -$17.25M -$9.640M -$11.98M
YoY Change 55.55% 75.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
21000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4875000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3520000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2019Q4 us-gaap Assets
Assets
106103000
CY2018Q4 us-gaap Assets
Assets
129006000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4147000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3603000
CY2019Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
21588000
CY2018Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8263000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18000
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29730000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
52315000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
7760000
CY2019Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
786000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4823000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
95414000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2273000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
229000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26663000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
833000
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
249000
CY2019Q4 us-gaap Liabilities
Liabilities
31529000
CY2018Q4 us-gaap Liabilities
Liabilities
13151000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
273966000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199427000
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity File Number
EntityFileNumber
001-38266
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7478000
CY2019Q2 dei Entity Public Float
EntityPublicFloat
150500000
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2019 dei City Area Code
CityAreaCode
857
CY2019 dei Local Phone Number
LocalPhoneNumber
242-1600
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34080000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
81363000
CY2018Q4 us-gaap Other Receivables
OtherReceivables
376000
CY2018Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
922000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
124219000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2893000
CY2018Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
233000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12318000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4617000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
254013000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138502000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115500000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65775000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15588000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-28000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18160525
CY2019 us-gaap Operating Expenses
OperatingExpenses
81363000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-63216000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1328000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
740000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2291000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41690000
CY2019 us-gaap Profit Loss
ProfitLoss
-60925000
CY2018 us-gaap Profit Loss
ProfitLoss
-41662000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-6000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
44000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60881000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84957000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
335000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2749000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15316000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
74574000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
355000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74574000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
115855000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106103000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129006000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2720
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3220
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2720
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3220
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19190695
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17205962
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19190695
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17205962
CY2019 us-gaap Revenues
Revenues
18147000
CY2018 us-gaap Revenues
Revenues
3966000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33885000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12887000
CY2018 us-gaap Operating Expenses
OperatingExpenses
46772000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-42806000
CY2019 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
223000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1101000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
43000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1144000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3776000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
750000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
409000
CY2019 spro Non Cash Lease Cost
NonCashLeaseCost
408000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-184000
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-248000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3776000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2749000
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-373000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
750000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
84000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
13610000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
671000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
7384000
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-635000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2654000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5497000
CY2019 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-299000
CY2018 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-770000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2912000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1192000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
564000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3575000
CY2018 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
554000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-52000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50020000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39625000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
88993000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
130175000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
118837000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49455000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
314000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2436000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29530000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83156000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15790000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
508000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
335000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16140000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69523000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4350000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53258000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34080000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87338000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29730000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
54000
CY2019Q2 spro Grant Revenue
GrantRevenue
2089000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of share-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Management evaluates its estimates<font style="font-size:12pt;"> </font>on an ongoing basis, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.&nbsp;&nbsp;</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and of Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </p>
CY2019 spro Entity Incorporation Month And Year
EntityIncorporationMonthAndYear
2013-12
CY2019 us-gaap Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
2017-06-30
CY2019 spro Business Combination Exchange Ratio
BusinessCombinationExchangeRatio
1
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-60900000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-41700000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3000000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5400000
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
52299000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
52315000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3788000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3720000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1515000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
827000
CY2019 us-gaap Lease Cost
LeaseCost
1479000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1234000
CY2019 spro Non Cash Amount Of Right Of Use Asset And Lease Obligation Incurred
NonCashAmountOfRightOfUseAssetAndLeaseObligationIncurred
1038000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1004000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentMember
CY2019Q4 spro Operating And Finance Lease Assets
OperatingAndFinanceLeaseAssets
5879000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5545000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
928000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
943000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1061000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1076000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1092000
CY2019Q4 spro Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
2969000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8069000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2524000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1361000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1054000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
995000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1107000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1123000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2246000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7886000
CY2019 spro Lessee Operating Lease Lease Not Yet Commenced Future Minimum Lease Payments
LesseeOperatingLeaseLeaseNotYetCommencedFutureMinimumLeasePayments
4300000
CY2019 spro Lessee Operating Lease Lease Not Yet Commenced Expected To Commence Year And Month
LesseeOperatingLeaseLeaseNotYetCommencedExpectedToCommenceYearAndMonth
2020-06
CY2019Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P7Y
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2019Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
17746000
CY2018Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4541000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2630000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2379000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
917000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
409000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000
CY2017Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
5.90
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3635225
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
489657
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2297810
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1041734
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78610
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
291506
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2969428
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.752
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.741
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2969428
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1339002
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.03
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.25
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.46
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.21
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.13
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.13
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.56
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M7D
CY2019Q3 spro Grant Revenue
GrantRevenue
4471000
CY2019Q4 spro Grant Revenue
GrantRevenue
2934000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-62623000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-33236000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1698000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-8426000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-60925000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y29D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
354000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6689000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6689000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3566000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-41662000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.030
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.026
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.067
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.054
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.008
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.019
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.011
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.012
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.304
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.259
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44239000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29025000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5220000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3385000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2521000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1731000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51980000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34141000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51980000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34141000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
156800000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
157800000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
7700000
CY2019 spro Ownership Change Increase In Ownership By Maximum Percentage
OwnershipChangeIncreaseInOwnershipByMaximumPercentage
0.50
CY2019 spro Ownership Change Increase In Ownership Percentage Term
OwnershipChangeIncreaseInOwnershipPercentageTerm
P3Y
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24519000
CY2019 spro Valuation Allowance Deferred Tax Asset Increase In Amount
ValuationAllowanceDeferredTaxAssetIncreaseInAmount
17839000
CY2018 spro Valuation Allowance Deferred Tax Asset Increase In Amount
ValuationAllowanceDeferredTaxAssetIncreaseInAmount
9622000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018 spro Tax Cuts And Jobs Act Of2017 Net Operating Losses Limitation Percentage
TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage
0.80
CY2017 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
9400000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5730178
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5517810
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2019Q1 spro Grant Revenue
GrantRevenue
3911000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3807000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
172000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
696000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
13414000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
15808000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
22628000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
29513000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-5072000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-13150000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-17717000
CY2019Q4 us-gaap Profit Loss
ProfitLoss
-24986000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17221120
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17667620
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18659079
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19052827
CY2018Q1 spro Grant Revenue
GrantRevenue
1153000
CY2018Q2 spro Grant Revenue
GrantRevenue
463000
CY2018Q3 spro Grant Revenue
GrantRevenue
658000
CY2018Q4 spro Grant Revenue
GrantRevenue
1692000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
11969000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
10434000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
11593000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
12776000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-10644000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-9956000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-10463000
CY2018Q4 us-gaap Profit Loss
ProfitLoss
-10599000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14369182
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14376529
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17471462
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17736996

Files In Submission

Name View Source Status
0001564590-20-010998-index-headers.html Edgar Link pending
0001564590-20-010998-index.html Edgar Link pending
0001564590-20-010998.txt Edgar Link pending
0001564590-20-010998-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gkqs0fi3tuf3000001.jpg Edgar Link pending
glhfjvi4d4cy000001.jpg Edgar Link pending
glhfjvi4d4cy000002.jpg Edgar Link pending
glhfjvi4d4cy000003.jpg Edgar Link pending
glhfjvi4d4cy000004.jpg Edgar Link pending
glhfjvi4d4cy000005.jpg Edgar Link pending
glhfjvi4d4cy000006.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-10k_20191231.htm Edgar Link pending
spro-20191231.xml Edgar Link completed
spro-20191231.xsd Edgar Link pending
spro-20191231_cal.xml Edgar Link unprocessable
spro-20191231_def.xml Edgar Link unprocessable
spro-20191231_lab.xml Edgar Link unprocessable
spro-20191231_pre.xml Edgar Link unprocessable
spro-ex1012_337.htm Edgar Link pending
spro-ex1013_338.htm Edgar Link pending
spro-ex106_372.htm Edgar Link pending
spro-ex211_7.htm Edgar Link pending
spro-ex231_10.htm Edgar Link pending
spro-ex311_14.htm Edgar Link pending
spro-ex312_13.htm Edgar Link pending
spro-ex321_11.htm Edgar Link pending
spro-ex322_6.htm Edgar Link pending
spro-ex43_371.htm Edgar Link pending